Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation

被引：0
|
作者：
Massarweh, S
Osborne, CK
Wakeling, AE
Schiff, R
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Astra Zeneca, Macclesfield, Cheshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [31] Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
    Croessmann, Sarah
    Formisano, Luigi
    Kinch, Lisa N.
    Gonzalez-Ericsson, Paula I.
    Sudhan, Dhivya R.
    Nagy, Rebecca J.
    Mathew, Aju
    Bernicker, Eric H.
    Cristofanilli, Massimo
    He, Jie
    Cutler, Richard E., Jr.
    Lalani, Alshad S.
    Miller, Vincent A.
    Lanman, Richard B.
    Grishin, Nick V.
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 277 - 289
  • [32] Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
    E. H. Lips
    L. Mulder
    J. J. de Ronde
    I. A. M. Mandjes
    A. Vincent
    M. T. F. D. Vrancken Peeters
    P. M. Nederlof
    J. Wesseling
    S. Rodenhuis
    Breast Cancer Research and Treatment, 2012, 131 : 827 - 836
  • [33] ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2− Breast Cancer
    Julia E. C. van Steenhoven
    T. van Dalen
    Annals of Surgical Oncology, 2019, 26 : 800 - 801
  • [34] SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
    Bellet, M.
    Morales Murillo, S.
    Gasol Cudos, A.
    Amillano, K.
    Chic, N.
    Gonzalez-Farre, X.
    Villagrasa, P.
    Ferrero-Cafiero, J. M.
    Pascual, T.
    Prat, A.
    Lange, C.
    Saura Manich, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S36 - S36
  • [35] Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
    Maryam Soleimani Dodaran
    Simone Borgoni
    Emre Sofyalı
    Pernette J. Verschure
    Stefan Wiemann
    Perry D. Moerland
    Antoine H. C. van Kampen
    BMC Cancer, 20
  • [36] Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer
    Dowsett, Mitch
    Kilburn, Lucy
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Pogue-Geile, Katherine
    Liu, Yuan
    Jacobs, Samuel A.
    Finnigan, Melanie
    Puhalla, Shannon
    Dodson, Andrew
    Martins, Vera
    Cheang, Maggie
    Perry, Sophie
    Holcombe, Chris
    Turner, Nick
    Swift, Claire
    Bliss, Judith M.
    Johnston, Stephen
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 163 - 174
  • [37] Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer
    Dodaran, Maryam Soleimani
    Borgoni, Simone
    Sofyali, Emre
    Verschure, Pernette J.
    Wiemann, Stefan
    Moerland, Perry D.
    van Kampen, Antoine H. C.
    BMC CANCER, 2020, 20 (01)
  • [38] Evaluation of ER, PgR, HER2 and Ki67 as predictors of response to neoadjuvant chemotherapy for operable breast cancer
    Burcombe, RJ
    Makris, A
    Richman, PI
    Pittam, M
    Daley, F
    Nobe, S
    Wilson, GD
    BRITISH JOURNAL OF CANCER, 2001, 85 : 50 - 50
  • [39] The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
    P Dubsky
    J C Brase
    R Jakesz
    M Rudas
    C F Singer
    R Greil
    O Dietze
    I Luisser
    E Klug
    R Sedivy
    M Bachner
    D Mayr
    M Schmidt
    M C Gehrmann
    C Petry
    K E Weber
    K Fisch
    R Kronenwett
    M Gnant
    M Filipits
    British Journal of Cancer, 2013, 109 : 2959 - 2964
  • [40] Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+breast cancer
    Turnbull, A. K.
    Webber, V.
    McStay, D.
    Arthur, L.
    Martinez-Perez, C.
    Fernando, A.
    Renshaw, L.
    Keys, J.
    Clarke, R.
    Sims, A. H.
    Dixon, J. M.
    CANCER RESEARCH, 2019, 79 (04)
12345